comparemela.com

Latest Breaking News On - Patrick mehlen - Page 1 : comparemela.com

Netris Pharma Raises €7 5M; Extends Series A to €24 4M

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Patrick mehlenNetris pharmaChief executive officerFabien sebilleChief business officer

A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy

A new drug prevents epithelial-mesenchymal transition, metastasis and resistance to anti-cancer therapy
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleJustine lengrandIevgenia pastushenkoPatrick mehlenSebastiaan vanuytvenUniversity of lyonCancer laboratoryResearch instituteStem cells

Netris pancreatic cancer study doses first patient

Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials - News - PharmaTimes

Patrick mehlenNetris pharmaGael rothClinical trial

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m FOLFIRINOX as first-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma March 29th, 2023 LYON, France —NETRIS Pharma, a clinical-stage private biopharmaceutical company developin.

Patrick mehlenCentre hospitalier universitaire grenoble alpesGael rothWestern europePrincipal investigator

Netris Pharma starts hepatocellular carcinoma study

Trial will evaluate efficacy of anti-netrin-1 antibody candidate NP137 in combination with Atezo-bev - News - PharmaTimes

Patrick mehlenNetris pharmaCentre hospitalier universitaire grenoble alpesGael roth

vimarsana © 2020. All Rights Reserved.